BMCM
VRTX icon

Bryn Mawr Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bryn Mawr Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-494
Closed -$224K – 467
2025
Q4 		$224K Buy
+494
New +$213K 0.01% 415
2025
Q3 		– Sell
-826
Closed -$368K – 458
2025
Q2 		$368K Buy
826
+370
+81% +$171K 0.02% 314
2025
Q1 		$221K Buy
+456
New +$212K 0.01% 363

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bryn Mawr Capital Management's VRTX Position: Q1 2026 in Review

Bryn Mawr Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 494 shares — an estimated $224K sold.

Bryn Mawr Capital Management first reported a position in VRTX in Q1 2025 and held it in 3 quarters. The position peaked at $368K in Q2 2025. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Bryn Mawr Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bryn Mawr Capital Management sold 494 Vertex Pharmaceuticals shares in Q1 2026, an estimated $224K.
  • Bryn Mawr Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Bryn Mawr Capital Management's Vertex Pharmaceuticals position peaked at $368K in Q2 2025.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q1 2026, filed 4 May 2026.